Sinopharm announces executive director resignation, new appointment

Sinopharm Group Co. Ltd. announced that Sun Jinglin resigned as an executive director and a member of the strategy and investment committee, effective November 6, 2025, due to work arrangements. Sun confirmed no disagreement with the board, which expressed gratitude for his contributions.

Concurrently, the board resolved to propose the appointment of Yang Binghua as an executive director, subject to shareholder approval at a general meeting. Yang, 45, holds a master's degree in public administration and has served in various leadership roles within state-owned entities, including deputy secretary of the party committee for Sinopharm since October 2025. He also previously held non-executive directorships at China Traditional Chinese Medicine Holdings Co. Limited (HKEX: 0570) and a directorship at Chongqing Taiji Industry (Group) Co., Ltd. (Shanghai Stock Exchange: 600129) within the last three years.

Upon approval, Yang's term will run until the current board session expires, with remuneration based on performance appraisal and incentive measures. The board comprises non-executive directors Zhao Bingxiang (chairman), Chen Qiyu, Zu Jing, Xing Yonggang, Chen Yuqing, Wen Deyong, and Feng Rongli; executive director Lian Wanyong (president); and independent non-executive directors Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru.